Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

193 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Notch regulation of tumor angiogenesis.
Bridges E, Oon CE, Harris A. Bridges E, et al. Future Oncol. 2011 Apr;7(4):569-88. doi: 10.2217/fon.11.20. Future Oncol. 2011. PMID: 21463145 Review.
DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo.
Li JL, Sainson RC, Oon CE, Turley H, Leek R, Sheldon H, Bridges E, Shi W, Snell C, Bowden ET, Wu H, Chowdhury PS, Russell AJ, Montgomery CP, Poulsom R, Harris AL. Li JL, et al. Among authors: bridges e. Cancer Res. 2011 Sep 15;71(18):6073-83. doi: 10.1158/0008-5472.CAN-11-1704. Epub 2011 Jul 29. Cancer Res. 2011. PMID: 21803743
A core human primary tumor angiogenesis signature identifies the endothelial orphan receptor ELTD1 as a key regulator of angiogenesis.
Masiero M, Simões FC, Han HD, Snell C, Peterkin T, Bridges E, Mangala LS, Wu SY, Pradeep S, Li D, Han C, Dalton H, Lopez-Berestein G, Tuynman JB, Mortensen N, Li JL, Patient R, Sood AK, Banham AH, Harris AL, Buffa FM. Masiero M, et al. Among authors: bridges e. Cancer Cell. 2013 Aug 12;24(2):229-41. doi: 10.1016/j.ccr.2013.06.004. Epub 2013 Jul 18. Cancer Cell. 2013. PMID: 23871637 Free PMC article.
ADAM10 mediates trastuzumab resistance and is correlated with survival in HER2 positive breast cancer.
Feldinger K, Generali D, Kramer-Marek G, Gijsen M, Ng TB, Wong JH, Strina C, Cappelletti M, Andreis D, Li JL, Bridges E, Turley H, Leek R, Roxanis I, Capala J, Murphy G, Harris AL, Kong A. Feldinger K, et al. Among authors: bridges e. Oncotarget. 2014 Aug 30;5(16):6633-46. doi: 10.18632/oncotarget.1955. Oncotarget. 2014. PMID: 24952873 Free PMC article.
193 results